Shares of NxStage Medical(NXTM) - Get Report have remained elevated since the dialysis system provider surprised Wall Street in November with a much narrower loss than expected. CEO Jeffrey Burbank said profitability is clearly within sight.

"We are right at the cusp of becoming profitable," said Burbank. "We've indicated that 2017 is probably the year for that, but if we do things really well, then 2016 may be the year." The Wall Street consensus estimate is that NxStage will lose 15 cents per share in 2016.

Shares of NxStage surged more than 22% last month after the company reported a third quarter loss of $1.7 million, or 3 cents per share, thoroughly beating the Wall Street consensus estimate of a loss of 8 cents per share. The medical device maker posted revenue of $86.5 million in the period, which also topped the Street's forecast of $82.1 million.

NxStage is forecasting revenue in the range of $86 million to $87 million for the quarter ending in December, and full-year revenue in the range of $332 million to $333 million. NxStage foresees a fourth quarter net loss of between $2 million to $3 million and a full-year net loss of between $15 and $16 million.

Home revenue increased 15% to $46.5 million for the third quarter of 2015 compared with $40.4 million for the third quarter of 2014. Burbank said the company has good visibility in this arena and should be able to repeat or improve on that performance in the current quarter and coming year.

Revenues from the critical care division increased 23% in its third quarter to $16.3 million compared with revenue of $13.3 million a year earlier. Burbank said this growth rate was way above the norm of 10% to 12%, and would likely come down.

Meanwhile, in-center revenue was flat at $19.4 million, the same as in the previous year. Burbank said this was due to the loss of a contract, but said the company has been reallocating that capacity to new customers.

"We think the comps year-over-year going into 2016 will be a little better for us in the in-center business as well," said Burbank.